Research programme: phytochemical-based therapeutics - KannaLife SciencesAlternative Names: Plant extracts-based therapeutics - KannaLife Sciences
Latest Information Update: 09 Sep 2014
At a glance
- Originator Merck & Co
- Developer KannaLife Sciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Brain injuries; Hepatic encephalopathy
Most Recent Events
- 20 Dec 2013 Early research in Hepatic encephalopathy in USA (unspecified route)
- 20 Dec 2013 Early research in Brain injuries in USA (unspecified route)